<DOC>
	<DOCNO>NCT01003691</DOCNO>
	<brief_summary>The purpose study determine safety tolerability multiple dos RN6G subject advance dry , age-related macular degeneration include geographic atrophy .</brief_summary>
	<brief_title>Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry , Age-Related Macular Degeneration Including Geographic Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Retinal Degeneration</mesh_term>
	<criteria>Be nonchild bear potential Diagnosis dry AMD include uni multifocal geographic atrophy without foveal involvement BCVA 20/50 good study eye Evidence ocular disease advance AMD GA study eye History diagnosis exudative ( wet ) AMD , subretinal choroidal neovascular lesion study eye Presence disease condition might compromise cardiovascular , hematological , renal , hepatic , pulmonary , endocrine , central nervous immune , gastrointestinal system Requires ocular systemic medication know toxic lens , retina optic nerve</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Phase 1b Advanced Dry Age-Related Macular Degeneration RN6G</keyword>
</DOC>